Results 161 to 170 of about 13,660 (185)

Biomarkers for neuromyelitis optica

Clinica Chimica Acta, 2015
Neuromyelitis optica (NMO) is an acquired, heterogeneous inflammatory disorder, which is characterized by recurrent optic neuritis and longitudinally extensive spinal cord lesions. The discovery of the serum autoantibody marker, anti-aquaporin 4 (anti-AQP4) antibody, revolutionizes our understanding of pathogenesis of NMO.
Kuo-Hsuan, Chang, Long-Sun, Ro, Rong-Kuo, Lyu, Chiung-Mei, Chen   +3 more
openaire   +2 more sources

Biotinidase Deficiency as a Mimic of Neuromyelitis Optica Spectrum Disorder in Childhood

JAMA Neurology, 2021
Jonathan Santoro
exaly  

Neuromyelitis Optica

Archives of Neurology, 2003
openaire   +2 more sources

Neuromyelitis Optica

American Journal of Ophthalmology, 1952
openaire   +2 more sources

CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder

Heliyon, 2021
Ichiro Nakashima, Kazuo Fujihara, Tatsuro Misu   +2 more
exaly  

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

Lancet, The, 2004
Brian Weinshenker, Ichiro Nakashima, Kazuo Fujihara   +2 more
exaly  

Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?

Multiple Sclerosis Journal, 2012
Su-Hyun Kim
exaly  

Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea

Multiple Sclerosis Journal, 2017
Byoung Joon Kim, Jong Kuk Kim, Ohyun Kwon   +2 more
exaly  

A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder

JAMA Neurology, 2013
Su-Hyun Kim, So-Young Huh, Ho Jin Kim
exaly  

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset

Multiple Sclerosis Journal, 2014
Nicolas Collongues, Aksel Siva, Ayse Altintas   +2 more
exaly